Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. It focuses on the development of CAN04 for the treatment of non-small cell lung cancer and pancreatic cancer. The company was founded by Thoas Michael Fioretos, Kjell Torsten Sjostrom, and Marcus Jaras on October 26, 2009 and is headquartered in Lund, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company